# NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07309289/  
OnCo record `nct07309289` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Shanghai Zhongshan Hospital, now recruiting.

## Summary

NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT07309289 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 144 participants, started 2025-07-01 and due to reach its primary completion in 2029-03-01. Interventions recorded: NALIRIFOX plus targeted therapy; FOLFOX plus targeted therapy. Conditions listed: Metastatic Colorectal Cancer (CRC). Primary outcome: 18 month PFS rate. Colorectal eligibility wording from the registry: "* Histopathologically confirmed patient with an inoperable metastatic colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07309289
- Phase: 3
- Setting: NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer: a Multicentre, Open-label, Randomised Trial
- Sponsor: Shanghai Zhongshan Hospital
- Enrolled: 144

## Sources

- ClinicalTrials.gov NCT07309289: https://clinicaltrials.gov/study/NCT07309289

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07309289.json